HLN
Haleon plc
There isn't enough reported data to score HLN yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Stable |
HLN's profitability is currently strong, and its balance sheet is stable. There isn't enough data to rate its revenue and cash flow.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HLN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $9.09 | — |
| Cheap | 20x | $4.96 | -45% |
| Fair | 26x | $6.41 | -30% |
| Expensive | 32x | $7.99 | -12% |
Historical ranges are pointers, not guarantees.
HLN's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over HLN in the historical PE scenario, which offers more potential upside but is not a forecast.
HLN Forward outlook
There aren't enough analyst estimates for HLN to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.25 | +19% |
| Q4 2024 | $0.21 | +40% |
| Q4 2023 | $0.15 | 0% |
HLN has the edge over NVO in the latest year-over-year earnings comparison.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
HLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $14.7B | +99% |
| Q4 2024 | $7.4B | -0.4% |
| Q2 2024 | $7.6B | -0.8% |
| Q4 2023 | $7.4B | -49% |
| Q4 2022 | $14.4B | +336% |
HLN has the edge over NVO in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 22% | +2 points |
| Q4 2024 | 19% | +2.2 points |
| Q2 2024 | 20% | -0.1 points |
| Q4 2023 | 15% | +0.7 points |
| Q2 2023 | 20% | N/A |
| Q4 2022 | 17% | N/A |
| Q4 2021 | 20% | N/A |
| Q2 2021 | 15% | N/A |
HLN's operating margin was 22% last quarter, up 2 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
HLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $3.1B | +79% |
| Q4 2024 | $1.7B | +4.5% |
| Q2 2024 | $1B | +21% |
| Q4 2023 | $1.6B | -30% |
| Q4 2022 | $2.3B | +$2.3B |
HLN's free cash flow has been positive every quarter since mid-2021: $7.5B over the past year, up 135% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
HLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -149M shares |
| 1 year | -2.6% | -238M shares |
HLN has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $200.9M |
| Q4 2024 | $267.4M |
| Q2 2024 | $421.7M |
| Q4 2021 | — |
| Q2 2021 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
HLN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.6x | Moderate |
| Q4 2024 | 3.1x | Elevated |
| Q2 2024 | 3.6x | Elevated |
| Q4 2023 | 3.7x | Elevated |
| Q4 2022 | 4.6x | High |
HLN's net debt is about 2.6 years of its operating earnings (EBITDA), down from 4.6 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
HLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 28.9 | Neutral |
HLN's weekly RSI is 46 (neutral) and its Stochastic is 29 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HLN PE vs Healthcare Sector
| Metric | HLN | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 6 | 45 | 39 pts below |
HLN is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over HLN on valuation relative to its sector.
HLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.33 | 2.6% below |
| 20 week MA | $9.60 | 5.3% below |
| 50 week MA | $9.75 | 6.8% below |
| 100 week MA | $9.83 | 7.5% below |
| 200 week MA | $9.25 | 1.7% below |
HLN is in a downtrend: it's below all five of its weekly moving averages, and 1.7% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over HLN on trend strength, trading above more of its moving averages.
HLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $7.41 | $8.00 | +8% |
| 2023 | $8.00 | $8.23 | +2.9% |
| 2024 | $8.23 | $9.64 | +17% |
| 2025 | $9.64 | $10.1 | +5.1% |
| 2026 YTD | $10.1 | $9.09 | -10% |
HLN has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.